These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 25416807)

  • 1. In vivo maintenance of human regulatory T cells during CD25 blockade.
    Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
    J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.
    Oh U; Blevins G; Griffith C; Richert N; Maric D; Lee CR; McFarland H; Jacobson S
    Arch Neurol; 2009 Apr; 66(4):471-9. PubMed ID: 19364932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2Rbeta links IL-2R signaling with Foxp3 expression.
    Soper DM; Kasprowicz DJ; Ziegler SF
    Eur J Immunol; 2007 Jul; 37(7):1817-26. PubMed ID: 17559173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-β production.
    Shen E; Zhao K; Wu C; Yang B
    Cell Biol Int; 2011 Jul; 35(7):705-12. PubMed ID: 21314640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy.
    Hire K; Ngo DK; Stewart-Maynard KM; Hering B; Bansal-Pakala P
    Cell Immunol; 2012; 274(1-2):83-8. PubMed ID: 22364726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
    Rech AJ; Vonderheide RH
    Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
    Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
    Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M; Milo R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS; Martin R
    Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients.
    Rech AJ; Mick R; Martin S; Recio A; Aqui NA; Powell DJ; Colligon TA; Trosko JA; Leinbach LI; Pletcher CH; Tweed CK; DeMichele A; Fox KR; Domchek SM; Riley JL; Vonderheide RH
    Sci Transl Med; 2012 May; 4(134):134ra62. PubMed ID: 22593175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody.
    Vignali D; Gürth CM; Pellegrini S; Sordi V; Sizzano F; Piemonti L; Monti P
    Transplantation; 2016 Sep; 100(9):1853-61. PubMed ID: 27306531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
    Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation.
    Wang Z; Xiao L; Shi BY; Qian YY; Bai HW; Chang JY; Cai M
    Transpl Immunol; 2008 Apr; 19(1):69-73. PubMed ID: 18346640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
    Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
    Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
    Sheridan JP; Robinson RR; Rose JW
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.